LPL Financial’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$703K Sell
89,501
-32,312
-27% -$158K ﹤0.01% 4742
2026
Q1
$425K Buy
121,813
+73,109
+150% +$263K ﹤0.01% 4909
2025
Q4
$167K Buy
48,704
+12,954
+36% +$57.8K ﹤0.01% 5498
2025
Q3
$180K Buy
35,750
+17,526
+96% +$77.2K ﹤0.01% 5385
2025
Q2
$62.5K Buy
+18,224
New +$45.4K ﹤0.01% 5338
2024
Q4
Sell
-13,313
Closed -$34.6K 5275
2024
Q3
$34.6K Sell
13,313
-5,750
-30% -$15.9K ﹤0.01% 5037
2024
Q2
$56.4K Sell
19,063
-46,680
-71% -$177K ﹤0.01% 4826
2024
Q1
$298K Buy
+65,743
New +$335K ﹤0.01% 4205

Other funds holding ABCL

LPL Financial's ABCL Position: Q2 2026 in Review

LPL Financial reduced its AbCellera Biologics (ABCL) stake by 27% in Q2 2026, selling an estimated $158K and leaving 89,501 shares worth $703K. The position accounts for ﹤0.01% of the portfolio, ranked #4742.

LPL Financial first reported a position in ABCL in Q1 2024 and has held it in 8 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • LPL Financial held 89,501 shares of AbCellera Biologics worth $703K as of Q2 2026.
  • LPL Financial sold 32,312 AbCellera Biologics shares in Q2 2026, an estimated $158K.
  • AbCellera Biologics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #4742 holding.
  • LPL Financial first reported a position in AbCellera Biologics in Q1 2024 and has held it in 8 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.